Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Shape Therapeutics to present at the ESGCT 32nd congress on an RNA-targeting gene therapy for Parkinson's Disease and a novel CNS AAV capsid.
-
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
-
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
-
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights
-
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal...
-
Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
-
Highly experienced in gene therapy dealmaking, Pettenaro will be driving Coave’s business development activities and establish its presence in the Boston biotech hub Paris, France, and Cambridge,...
-
Paris, France, April 9, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, announces that members of its leadership team will be attending the following...
-
AAVantgarde announces 2 presentations at ARVO 2025 annual meeting
-
Copenhagen, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Gene therapy's biggest obstacle isn't science - it's manufacturing. While the field races forward with breakthrough treatments, production remains stuck...